Inhibition of the norepinephrine transporter by χ‐conotoxin dendrimers

  title={Inhibition of the norepinephrine transporter by $\chi$‐conotoxin dendrimers},
  author={Jingjing Wan and Andreas Brust and Rebecca F. Bhola and Prerna Jha and Mehdi Mobli and Richard James Lewis and Macdonald J. Christie and Paul F. Alewood},
  journal={Journal of Peptide Science},
  pages={280 - 289}
Peptide dendrimers are a novel class of macromolecules of emerging interest with the potential of delayed renal clearance due to their molecular size and enhanced activity due to the multivalency effect. In this work, an active analogue of the disulfide‐rich χ‐conotoxin χ‐MrIA (χ‐MrIA), a norepinephrine reuptake (norepinephrine transporter) inhibitor, was grafted onto a polylysine dendron. Dendron decoration was achieved by employing copper‐catalyzed alkyne–azide cycloaddition with azido‐PEG… 
6 Citations
Blockade of Human α7 Nicotinic Acetylcholine Receptor by α-Conotoxin ImI Dendrimer: Insight from Computational Simulations
This study provides novel insights into the binding mechanism of α-ImI dendrimer to hα7 nAChR, and the methodology reported here opens an avenue for the design of more selective dendedrimers with potential usage as drug/gene carriers, macromolecular drugs, and molecular probes.
Discovery of a Novel Cysteine Framework XXIV Conotoxin from Conus striatus, S24a, with Potential Analgesic Activity
A novel conotoxin, S24a, containing 26 amino acid residues was first derived from the cDNA library of Conus striatus . This conotoxin has the same conserved signal peptide as A-superfamily conotoxins
Molecular Engineering of Conus Peptides as Therapeutic Leads.
The molecular engineering approaches that have been used to modify these conotoxins to improve their pharmacological properties, including potency, selectivity, stability, and minimisation of the bioactive pharmacophore are discussed.
Click and Bioorthogonal Chemistry: The Future of Active Targeting of Nanoparticles for Nanomedicines?
This study identifies the main strategies offered by click and bioorthogonal chemistry, with respect to passive and active targeting, for NP functionalization with specific and multiple properties for imaging and cancer therapy.
Identification of Novel Conopeptides and Distinct Gene Superfamilies in the Marine Cone Snail Conus quercinus
  • Han Zhang, Lei Wang, +5 authors Xinghua Pan
  • Frontiers in Marine Science
  • 2021
Conopeptides from the marine cone snails are a mixture of cysteine-rich active peptides, representing a unique and fertile resource for neuroscience research and drug discovery. The ConoServer
Toxins in pain
Purpose of review Pain is a distressing protective sensory experience warning of actual or potential tissue damage. Natural toxins have evolved to exploit pain and related neuronal pathways to


Discovery and development of the χ-conopeptide class of analgesic peptides.
  • R. Lewis
  • Chemistry, Medicine
    Toxicon : official journal of the International Society on Toxinology
  • 2012
An extensive analoguing program identified Xen2174 to have improved stability and extended duration of analgaesia, without compromising efficacy versus side effects window observed for χ-MrIA, and is entering a Phase IIb double-blind study to determine safety and efficacy in bunionectomy pain.
α-Conotoxin dendrimers have enhanced potency and selectivity for homomeric nicotinic acetylcholine receptors.
Findings indicate that multimeric ligands can significantly enhance conotoxin potency and selectivity at homomeric nicotinic ion channels.
Solution structure of chi-conopeptide MrIA, a modulator of the human norepinephrine transporter.
The chi-conopeptides MrIA and MrIB are 13-residue peptides with two disulfide bonds that inhibit human and rat norepinephrine transporter systems and are of significant interest for the design of
Anti-allodynic efficacy of the χ-conopeptide, Xen2174, in rats with neuropathic pain
Xen2174 appears to be a promising candidate for development as a novel therapeutic for i.t. administration to patients with persistent neuropathic pain, after confirming the noradrenergic mechanism of action.
Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression.
Multimerization of the cyclic Ac-TZ14011 peptide reduces the negative influence of the multimodal label on the receptor affinity and the biodistribution.
chi-Conopeptide pharmacophore development: toward a novel class of norepinephrine transporter inhibitor (Xen2174) for pain.
A pharmacophore model for the allosteric binding of 3 to NET is proposed and it is shown that 3 interacts with NET predominantly through amino acids in the first loop, forming a tight inverse turn presenting amino acids Tyr7, Lys8, and Leu9 in an orientation allowing for high affinity interaction with NET.
Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers.
The design and synthesis of a series of Tyr(3)-octreotide-containing monomeric, dimeric, and tetrameric dendrimeric conjugates, which have high affinities for the SSTR2 receptor were described and determined by a competitive binding assay on rat brain sections.
64Cu-Labeled LyP-1-Dendrimer for PET-CT Imaging of Atherosclerotic Plaque
The results suggest that the (LyP- 1)4-dendrimer can be applied for in vivo PET imaging of plaque and that LyP-1 could be further exploited for the delivery of therapeutics with multivalent carriers or nanoparticles.
Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy.
The in vivo toxicity evaluation demonstrates that nanoparticle substantially avoids DOX-related toxicities and presents good biosafety without obvious side effects to normal organs of both tumor-bearing and healthy mice.
Inhibition of the norepinephrine transporter by the venom peptide chi-MrIA. Site of action, Na+ dependence, and structure-activity relationship.
The inhibitory effect of chi-MrIA was found to be dependent on Na+ with the conopeptide becoming a less effective blocker of [3H]norepinephrine by the NET under the conditions of reduced extracellular Na+, similar to the antidepressant inhibitors of the NET.